Cardiorenal Syndrome

• Type 1 — acute cardiorenal: abrupt cardiac decompensation (acute decompensated heart failure, acute coronary syndrome, cardiogenic shock) causing acute kidney injury. This is the type behind most inpatient "the creatinine is climbing" questions.
• Type 2 — chronic cardiorenal: chronic heart failure driving progressive chronic kidney disease.
• Type 3 — acute renocardiac: abrupt kidney injury causing cardiac dysfunction — volume overload and pulmonary oedema, arrhythmia from hyperkalaemia, uraemic pericarditis.
• Type 4 — chronic renocardiac: chronic kidney disease accelerating cardiovascular disease, through left ventricular hypertrophy, vascular calcification and accelerated atherosclerosis.
• Type 5 — secondary: a systemic illness striking both organs at once (sepsis, amyloidosis, systemic lupus erythematosus, cirrhosis, diabetes).

Cardiac triggers (types 1 and 2)

• Acute decompensated heart failure, with either reduced or preserved ejection fraction. Preserved-EF disease is at least as likely to produce cardiorenal physiology, because the congestion is what drives it.
• Acute coronary syndrome and cardiogenic shock, where low forward flow dominates.
• Right ventricular failure and severe tricuspid regurgitation — a particularly potent cause, because they raise central venous pressure directly.
• Constrictive pericarditis and cardiac tamponade, which raise venous pressure with a normal ejection fraction.
• Arrhythmia (rapid atrial fibrillation), massive pulmonary embolism, post-cardiotomy states.

Renal triggers (types 3 and 4)

• Any cause of acute kidney injury — volume overload, hyperkalaemia and metabolic acidosis all impair cardiac function.
• Chronic kidney disease, through pressure and volume overload, uraemic cardiomyopathy, mineral–bone disorder with vascular calcification, and anaemia.

Risk factors for developing worsening renal function during a heart failure admission

• Pre-existing chronic kidney disease — consistently the strongest predictor.
• Diabetes mellitus, older age, hypertension, prior episodes of worsening renal function.
• Higher baseline diuretic requirement, a marker of more advanced disease.
• Nephrotoxic exposure: NSAIDs, iodinated contrast, aminoglycosides, calcineurin inhibitors.
• Anaemia and iron deficiency, which travel with both organ failures and worsen both — sometimes labelled the cardiorenal anaemia syndrome.

Venous congestion — the dominant mechanism

• Elevated right-sided filling pressure is transmitted backwards to the renal veins. Because the kidney is enclosed in a non-compliant capsule, the resulting interstitial oedema raises intracapsular pressure, compressing tubules and peritubular capillaries and lowering the net filtration gradient further.
• Raised intra-abdominal pressure from ascites and gut oedema compounds this, and abdominal decompression can improve renal function in selected patients.
• This is the point most often missed. Haemodynamic studies in advanced decompensated heart failure — the best known by Mullens and colleagues — found that elevated central venous pressure correlated with worsening renal function more strongly than cardiac index did. A congested patient with a normal cardiac output can still have a falling GFR.

Reduced forward flow

• Low cardiac output lowers renal artery perfusion. Autoregulation defends GFR across a wide range, so this alone is rarely enough until output falls substantially, but it becomes dominant in cardiogenic shock and the "cold and wet" profile.

Neurohormonal amplification — why the loop closes

• Reduced effective arterial blood volume activates the renin–angiotensin–aldosterone system, the sympathetic nervous system and non-osmotic arginine vasopressin release.
• Angiotensin II constricts the efferent arteriole, which defends filtration fraction in the short term, while aldosterone and vasopressin drive sodium and water retention.
• That retained sodium and water raises venous pressure further, which lowers GFR further, which activates the system further. The loop is the disease.

Consequences of the efferent-tone dependence

• Because filtration is being propped up by angiotensin II–mediated efferent constriction, starting or up-titrating an ACE inhibitor, ARB or ARNI predictably drops GFR and raises creatinine. This is expected physiology, not injury, and is not by itself a reason to stop the drug.
• The same dependence explains why NSAIDs are so damaging here: blocking prostaglandin-mediated afferent dilation removes the other half of the autoregulatory pair.

Tubular and inflammatory contributions

• Tubuloglomerular feedback: increased distal sodium delivery is sensed by the macula densa and generates adenosine-mediated afferent vasoconstriction, reducing GFR.
• Systemic inflammation, oxidative stress and endothelial dysfunction contribute to bidirectional injury, particularly in the chronic types.

Congestion is the finding to look for, not hypotension

• Elevated jugular venous pressure and a positive hepatojugular reflux — the most useful bedside signs, since they track the venous pressure that is driving the kidney injury.
• Peripheral oedema, ascites, hepatomegaly with right upper quadrant discomfort, and in advanced cases congestive hepatopathy.
• Orthopnoea, paroxysmal nocturnal dyspnoea, weight gain.
• A third heart sound and pulmonary crackles may be present but are insensitive in chronic disease.

Renal features

• Rising creatinine and urea during a heart failure admission, often with a disproportionate rise in urea relative to creatinine from enhanced proximal reabsorption.
• Oliguria and a diminishing response to a previously effective diuretic dose (diuretic resistance).
• Hyponatraemia, reflecting vasopressin-driven free water retention — a marker of severity and an adverse prognostic sign.

Haemodynamic profiles worth recognising

• "Warm and wet" — congested with preserved perfusion. The most common profile, and the one where the venous-congestion mechanism dominates. Treat with decongestion.
• "Cold and wet" — congested and hypoperfused, with narrow pulse pressure, cool extremities and mental slowing. This is the subgroup where low output matters and where inotropic support may be considered.

Establish that renal function is worsening

• Apply standard KDIGO acute kidney injury criteria — a rise in serum creatinine of ≥0.3 mg/dL within 48 hours, a rise to ≥1.5 times baseline within 7 days, or urine output below 0.5 mL/kg/h for 6 hours. Note that the older heart failure literature used varying thresholds, so reported incidence differs between studies.

Establish that the patient is congested, not dry

• Bedside assessment of jugular venous pressure, with echocardiography for ejection fraction, right ventricular function, estimated filling pressures and inferior vena cava size and collapsibility.
• Point-of-care ultrasound is increasingly used to grade venous congestion, including protocols that combine IVC diameter with Doppler patterns in the hepatic, portal and intrarenal veins. This is a developing area rather than a guideline-mandated standard, and you are unlikely to be examined on the scoring detail.
• Right heart catheterisation when the volume status genuinely cannot be determined clinically, and management hinges on it.

Urinalysis — the highest-yield discriminator

• Bland sediment with no casts supports cardiorenal physiology.
• Muddy brown granular casts indicate acute tubular necrosis.
• White cell casts, eosinophiluria and rash suggest acute interstitial nephritis.
• Dysmorphic red cells and red cell casts indicate glomerulonephritis.

Sodium indices, with a caveat

• A fractional excretion of sodium (FENa) below 1% fits the prerenal/cardiorenal pattern, but nearly every one of these patients is already on a loop diuretic, which invalidates it.
• Fractional excretion of urea (FEUrea) below about 35% is the better test in a diuretic-treated patient.

Natriuretic peptides

• BNP and NT-proBNP support a cardiac cause of the congestion, but both rise as GFR falls, and NT-proBNP more so because of its renal clearance. Interpret against higher thresholds in chronic kidney disease rather than treating a raised value as proof of decompensation.

Actively exclude the alternatives before settling on the label

• Obstruction — a post-void bladder scan or renal ultrasound.
• Bilateral renal artery stenosis unmasked by RAAS blockade, particularly with a creatinine rise beyond 30% or flash pulmonary oedema.
• Contrast-associated injury, cholesterol embolisation (livedo reticularis, eosinophilia, low complement after an arterial procedure), and drug-induced injury.

Loop diuretics — first line

• Give intravenously, since gut oedema makes oral absorption unreliable.
• Start at at least 1 to 2.5 times the home oral dose in intravenous equivalents. The DOSE trial compared low-dose with high-dose and bolus with continuous infusion: there was no significant difference in the co-primary endpoints, though the higher-dose strategy produced greater symptom relief and more transient creatinine rise. Bolus and infusion performed comparably.
• Assess the response early rather than waiting a day. A spot urine sodium measured about two hours after the dose, and urine output over the first six hours, identify an inadequate response promptly; European Society of Cardiology heart failure position statements suggest a spot urine sodium above roughly 50–70 mmol/L indicates an adequate natriuretic response.

Diuretic resistance — sequential nephron blockade

• Add a thiazide-type agent (metolazone, or intravenous chlorothiazide) to block distal compensatory sodium reabsorption. The CLOROTIC trial showed adding hydrochlorothiazide improved weight loss and diuresis, with more biochemical worsening of renal function.
• Add acetazolamide. The ADVOR trial found that acetazolamide added to intravenous loop diuretics increased the rate of successful decongestion.
• Increase the loop dose or move to a continuous infusion before declaring resistance, and check that dietary sodium and intravenous fluid carriers are not undoing the work.

Disease-modifying therapy — do not withhold it for the creatinine

• SGLT2 inhibitors are a Class 1 recommendation in heart failure with reduced ejection fraction in the 2022 AHA/ACC/HFSA guideline, with benefit also established across preserved ejection fraction. They cause a small, expected early dip in eGFR and then slow long-term decline. They are among the few agents that help both organs.
• ACE inhibitors, ARBs or ARNI: a rise in creatinine of up to about 30% that then stabilises is generally accepted and is not a reason to discontinue. A larger or progressive rise, or hyperkalaemia, should prompt evaluation for volume depletion, bilateral renal artery stenosis or a nephrotoxin.
• Mineralocorticoid receptor antagonists improve outcomes but require potassium and renal monitoring. Potassium binders can make continued RAAS blockade possible in a patient who would otherwise have to stop.
• Beta blockers should generally be continued in the absence of hypoperfusion, and up-titrated once the patient is decongested.

Inotropes — narrow indication

• Reserve for the hypoperfused, "cold and wet" patient. They improve forward flow at the cost of arrhythmia and, in trials, no mortality benefit.
• Low-dose dopamine is not renoprotective. The ROSE-AHF trial found that neither low-dose dopamine nor low-dose nesiritide added to diuretic therapy improved decongestion or renal function. The old "renal dose dopamine" concept is obsolete.

Ultrafiltration — not first line

• CARRESS-HF compared ultrafiltration with a stepped pharmacological care algorithm in acute heart failure with worsening renal function. Stepped pharmacological care was superior for the bivariate endpoint of creatinine change and weight loss at 96 hours, and ultrafiltration produced more adverse events.
• Reserve it for genuine diuretic resistance, and renal replacement therapy for the standard indications — refractory hyperkalaemia, acidosis, volume overload, uraemic complications and certain intoxications.

Supportive measures

• Correct iron deficiency. Intravenous iron improves symptoms and functional capacity in heart failure with iron deficiency, with or without anaemia.
• Withdraw NSAIDs and avoidable nephrotoxins; minimise contrast exposure.
• Restrict sodium; individualise fluid restriction rather than applying it reflexively.
• Treat the precipitant — ischaemia, arrhythmia, infection, non-adherence.

• Diuretic resistance and progressive congestion, the pathway to refractory heart failure.
• Electrolyte and acid–base disturbance: hypokalaemia and hypomagnesaemia from loop and thiazide therapy, hyperkalaemia from RAAS blockade and falling GFR, hyponatraemia from vasopressin excess, and contraction metabolic alkalosis.
• Progression to chronic kidney disease and end-stage renal disease, particularly after repeated episodes.
• Drug accumulation and toxicity as GFR falls — digoxin is the classic example, with toxicity potentiated by the hypokalaemia the diuretics create.
• Recurrent hospitalisation and high mortality; worsening renal function that persists after decongestion carries a notably worse prognosis than a transient rise.
• Uraemic complications in type 3 disease: pericarditis, encephalopathy, platelet dysfunction with bleeding.

The single most testable concept

• Venous congestion, not low cardiac output, is the dominant driver in most patients. Elevated central venous pressure correlates with worsening renal function better than cardiac index does. A patient can have a normal ejection fraction, a normal blood pressure and a failing kidney purely from back-pressure.

The classic trap

• A congested heart failure patient with a rising creatinine and a bland urine looks "prerenal" — and giving fluid makes it worse. The correct answer is almost always more effective decongestion, not volume.

Discriminators to have ready

• Bland sediment → cardiorenal. Muddy brown granular casts → acute tubular necrosis. White cell casts with eosinophiluria → acute interstitial nephritis.
• FENa <1% fits, but is unreliable on diuretics — use FEUrea <35% instead.
• NT-proBNP rises as GFR falls; use higher thresholds in chronic kidney disease rather than reading any elevation as decompensation.

Drug rules examiners like

• A creatinine rise up to ~30% after starting an ACE inhibitor or ARB is expected and the drug should be continued. A larger or progressive rise should raise suspicion of bilateral renal artery stenosis or volume depletion.
• NSAIDs are especially harmful here — they remove prostaglandin-mediated afferent dilation while angiotensin II is holding up the efferent side.
• "Renal dose" dopamine does not exist. ROSE-AHF settled this.

Trials worth recognising by name

• DOSE — high versus low dose, bolus versus infusion loop diuretic; no significant difference in co-primary endpoints.
• CARRESS-HF — stepped pharmacological care beat ultrafiltration; ultrafiltration is not first line.
• ROSE-AHF — low-dose dopamine and nesiritide gave no renal or decongestive benefit.
• ADVOR — acetazolamide added to loop diuretics improved decongestion.

The five types, in one line each

• 1 acute heart → acute kidney. 2 chronic heart → chronic kidney. 3 acute kidney → acute heart. 4 chronic kidney → chronic heart. 5 systemic disease → both. Odd numbers are acute, even numbers chronic; types 1 and 2 start with the heart, 3 and 4 with the kidney.